Printer Friendly

Browse Cabazitaxel topic

Articles

1-16 out of 16 article(s)
Title Author Type Date Words
Supply Of Expensive Anti-cancer Drugs To The Needs Of Kot - V.tarnovo Eood. Apr 2, 2019 404
Coffee compounds may reduce prostate cancer risk. Mar 19, 2019 325
Supply Of Expensive Anti-cancer Drugs To The Needs Of Kot - V.tarnovo Eood. Mar 18, 2019 402
Systemic Therapy in Metastatic Castration-Resistant Prostate Cancer/Metastatik Kastrasyona Direncli Prostat Kanserinde Sistemik Tedavi. Dulgar, Ozgecan; Yilmaz, Mesut; Tural, Deniz Nov 1, 2018 2940
Possible Role of Ga-68 PSMA PET/CT in Evaluation of Systemic Treatment Response in Patients with Metastatic Prostate Cancer/Metastatik Prostat Kanserli Hastalarda, Ga-68 Prostat Spesifik Membran Antijen PET/BT'nin Sistemik Tedavi Yaniti Degerlendirilmesinde Olasi Rolu. Sivrikoz, Ilknur Ak Nov 1, 2018 4357
Ra-223 Alpha Treatment in Prostate Cancer/Prostat Kanserinde Ra-223 Alfa Tedavi. Selcuk, Nalan Alan; Yencilek, Faruk Nov 1, 2018 2165
Lu-177 Prostate Specific Membrane Antigen Therapy of Metastatic Castration Resistant Prostate Cancer/Prostat Kanserinde Lu-177 Prostat Spesifik Membran Antijeni Tedavisi. Demirci, Emre; Kabasakal, Levent Nov 1, 2018 3341
Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel. Yokom, Daniel W.; Stewart, John; Alimohamed, Nimira S.; Winquist, Eric; Berry, Scott; Hubay, Stacey; Report Aug 1, 2018 6007
Evaluation of Tumor Viability for Primary and Bone Metastases in Metastatic Castration-Resistant Prostate Cancer Using Whole-Body Magnetic Resonance Imaging. Iwamura, Hiromichi; Kaiho, Yasuhiro; Ito, Jun; Anan, Go; Satani, Nozomi; Matsuura, Tomonori; Tamura, Jan 1, 2018 3463
Neutrophil-to-Lymphocyte Ratio Predicts Prognosis in Castration-Resistant Prostate Cancer Patients Who Received Cabazitaxel Chemotherapy. Uemura, Koichi; Kawahara, Takashi; Yamashita, Daisuke; Jikuya, Ryosuke; Abe, Koichi; Tatenuma, Tomoy Report Jan 1, 2017 3550
Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone. Saad, Fred; Winquist, Eric; Hubay, Stacey; Berry, Scott; Assi, Hazem; Levesque, Eric; Aucoin, Nathal Clinical report Mar 1, 2016 6468
Assessing the utility of cabazitaxel in mCRPC. North, Scott A. Report Mar 1, 2016 1406
Optimal management of patients receiving cabazitaxel-based chemotherapy. Sperlich, Catherine; Saad, Fred Report Feb 1, 2013 5351
Chemotherapy for prostate cancer: Clinical practice in Canada. Saad, Fred; Asselah, Jamil Report Feb 1, 2013 3448
Post-docetaxel options for further survival benefit in metastatic castration-resistant prostate cancer: Questions of choice. Asselah, Jamil; Sperlich, Catherine Report Feb 1, 2013 3029
FDA clears two prostate medications. Jul 19, 2010 383

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters